United States Xerostomia Therapeutics Market 2025 | Growth Drivers, Competitive Landscape & Investment Opportunities

Market Size and Growth

Xerostomia Therapeutics Market is estimated to reach at a CAGR of 3.8% during the forecast period (2024-2031).

Key Development:

United States: Recent Industry Developments

✅ In October 2025, GSK announced positive findings from its clinical studies aimed at novel treatments for xerostomia, signaling a significant advancement in dry mouth management.

✅ In October 2025, MeiraGTx received recognition for its innovative approaches towards radiation-induced xerostomia, marking a step forward in targeted therapeutic solutions.

Japan: Recent Industry Developments

✅ In October 2025, the xerostomia therapeutic market in Japan is experiencing significant growth, driven by increasing awareness, technological advancements, and a rising prevalence of dry mouth conditions.

✅ In October 2025, local manufacturers in Japan are investing in research and development to introduce innovative formulations tailored to regional needs, enhancing treatment options for xerostomia.

✅ In October 2025, government initiatives in Japan aimed at enhancing disease recognition and treatment adoption are playing a vital role in expanding the xerostomia therapeutics market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/xerostomia-therapeutics-market?sb

Xerostomia therapeutics are treatments designed to relieve dry mouth caused by reduced saliva production. These include salivary stimulants, substitutes, and oral care products that improve moisture, comfort, and oral health, enhancing quality of life for patients with conditions like Sjögren's syndrome, cancer therapy side effects, or medication-induced dry mouth.

Recent Market Dynamics:

United States: Market Dynamics
✅ In October 2025, the U.S. xerostomia therapeutics market was set to witness significant growth by 2032, driven by key players like Biotene, SalivaMAX, and OraCoat.

✅ In October 2025, a survey revealed a strong association between xerostomia and medication use, with a high prevalence of xerostomia (43.6%) among adults in primary care centers. Polypharmacy was particularly associated with a high prevalence of xerostomia (71.2%) among older adults.

✅ In October 2025, researchers reported progress in gene therapy aimed at restoring salivary function in head and neck cancer survivors, showing potential for future treatments for radiation-induced xerostomia.

Key Players:

=> GlaxoSmithKline, Colgate-Palmolive Company, Acacia Pharma Group plc, Hikma Pharmaceuticals plc, Lupin Ltd., Parnell Pharmaceuticals Inc., Pendopharm, Virginia Head and Neck Therapeutics, Inc., Pfizer Inc. and Sun Pharmaceutical Industries Ltd.

Growth Forecast Projected:

The Global Xerostomia Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Xerostomia Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=xerostomia-therapeutics-market

Key Segments:

➥ By Type: OTC, Prescription

➥ By Product Type: Salivary Stimulants, Salivary Substitutes, Dentifrices, Artificial Saliva, Salivary Pen

➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Analysis for Xerostomia Therapeutics Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Xerostomia Therapeutics producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Xerostomia Therapeutics revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/xerostomia-therapeutics-market?sb

FAQ

Q: What is the growth rate of the Xerostomia Therapeutics Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 3.8% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.